-
AtoZ研究
Aggrastat-PhaseoftheAGGRASTATtoZOCOR(AtoZ)TrialComparisonofthesafetyandefficacyofunfractionatedheparinversusenoxaparinincombinationwithtirofibanandaspirininindividualswhopresentwithnon-STelevationacutecoronarysyndromesPresentedatACC2003LateBreakingClinicalTrialsBackgroundEnoxaparin(ENOX)hasdemonstra...
-
替罗非班对挤压模型中微血管血栓形成的影响
...J博士及其同事评估了糖蛋白IIb/IIIa抑制剂盐酸替罗非班(Aggrastat)在挤压伤吻合术模型中预防术后血栓形成的作用。科研人员利用大鼠股动脉建立挤压伤模型,并施行端-端微血管修补术。在完成最后的缝合前于血管腔内使用1ml...
-
IntravenousTirofibanWithIntra-ArterialUrokinaseandMechanicalThrombolysisinStroke
...haprocedurestartingwithanintravenousbolusoftheGPIIb/IIIainhibitortirofiban(Aggrastat;Merck),followedbymechanicalclotdisruptioncombinedwithlocallydeliveredurokinase,andcontinuingwiththeinfusionoftirofibanthroughoutandafter(for48hours)theinterventionalmaneuvers.MaterialsandMethodsBetweenAprilandDecemb...
-
治疗血栓性疾病药物的研究进展
...他不良反应有低血压,但不严重。2.3替罗非班(tirofiban,aggrastat,tirofibanhydmchloride)为化学合成的非肽类药。它有两种作用:一是通过对磷酸腺苷(adenosine5’—diphosphate,ADP)的抑制来抗血栓,其选择性较强,替罗非班t1/2约2h,约65%...
-
TheInflammatoryRoleofPlateletsinCysticFibrosis
...eceptorantagonists(abciximab[ReoPro],eptifibatide[Integrilin],andtirofiban[Aggrastat])haveprovenclinicalbenefitincoronaryarterydisease(73,74).ThereisgoodevidencethatalloftheseADPreceptorantagonistsandGPIIb-IIIaantagonistsinhibitsystemicinflammationinthedosesusedtotreatadultcardiovasculardisease(75...